Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis-Reference-Cited by-同舟云学术

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

Published:2021-11-17 Issue:12 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Almeida Deepak¹,Converse Paul J.¹,Li Si-Yang¹,Upton Anna M.²,Fotouhi Nader²,Nuermberger Eric L.¹³^ORCID

Affiliation:

1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Global Alliance for TB Drug Development, New York, New York, USA

3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Abstract

Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Funder

Bill and Melinda Gates Foundation

Bundesministerium für Bildung und Forschung

Department of Foreign Affairs and Trade, Australian Government

Foreign and Commonwealth Office

Irish Aid

Ministerie van Buitenlandse Zaken

United States Agency for International Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01412-21

Reference48 articles.

1. Approval of Novel TB Drug Celebrated—With Restraint

2. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

3. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

4. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

5. Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges;Expert Review of Anti-infective Therapy;2024-09-04

2. Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects;Antimicrobial Agents and Chemotherapy;2024-08-28

3. Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis;The Journal of Infectious Diseases;2024-06-28

4. Contribution of telacebec to novel drug regimens in a murine tuberculosis model;2024-06-27

5. Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease;Nature Reviews Drug Discovery;2024-02-28